Osteoarthritis (OA) is a painful, degenerative condition that is characterized by the gradual development of joint pain, as well as joint stiffness and limitation of movement in the joints. Of these symptoms, the chief complaint among individuals with OA is pain, which we estimate affected nearly 65 million individuals in the United States and Europe in 2016. Despite multiple available therapies spanning several drug classes, no truly novel therapies effective at treating OA pain have launched in more than a decade, and existing analgesics’ efficacy and/or safety and tolerability profiles leave room for improvement.
- What are the main treatment drivers and goals for OA pain?
- What are surveyed rheumatologists’ opinions of the relative performance of select therapies, including celecoxib (Pfizer’s Celebrex, generics) and Vivlodex (Iroko), on key efficacy, safety/tolerability, and convenience of administration attributes related to OA pain?
- Which clinical attributes are key influencers of physician prescribing decisions, which have limited impact, and which are hidden opportunities?
- What trade-offs in price and drug performance across select clinical attributes are acceptable to U.S. and European rheumatologists for a hypothetical new OA pain drug?
Unmet Need: Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
- Osteoarthritic Pain - Unmet Need - Detailed, Expanded Analysis (US/EU)
Author(s): Natalie Taylor, PhD; Dr. Ankuri Setia, BDS, PGDHM
Natalie Taylor, Ph.D. is a Principal Business Insights Analyst with the central nervous system/ophthalmology disorders team at Decision Resources Group. She has over ten years of experience authoring primary and market research reports for pharmaceutical industry clients across multiple psychiatry, pain, neurology, and ophthalmology therapy areas.
Prior to joining DRG, Dr. Taylor worked at QuintilesIMS as manager of the central nervous system portfolio of Disease Insights market forecasting offerings. She completed her Ph.D. in Physiology at Dartmouth College in Hanover, New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a B.S. in Biology from Dickinson College in Carlisle, Pennsylvania.
Dr. Ankuri Setia is a Biopharma Insight Analyst in the CNS team at Decision Resources Group.
She comes with a work experience of 2 years as Knowledge Management Associate with practice across multiple therapy areas and indications on various functions in secondary research, competitive intelligence and product profiling, market assessment and pipeline analysis, and clinical trials assessment. She earned a Master of Healthcare Management degree from Institute of Health Management Research, a Deemed University.